Collaborators believe that this technique will enable quicker compound identification.

ActiveSight will collaborate on a fragment-based lead discovery (FBLD) project with CHDI related to Huntington’s disease (HD). The companies hope that the FBLD approach will lead to therapies in shorter time periods than conventional methods.

ActiveSight will screen libraries using x-ray crystallography to visualize fragments that bind to a CHDI-selected HD target. The fragments will then be linked or grown into larger, drug-like compounds. These are thought to be more efficiently binding than compounds resulting from HTS methodologies, according to the firms.

Previous articleLigoCyte and Biogen Idec Ally to Develop Anti-CD103 Drugs
Next articleOxford Genome Sciences Partners with Medarex and Biosite to Enhance Oncology Pipeline